Endonovo Therapeutics (ENDV) Total Liabilities (2016 - 2023)
Endonovo Therapeutics has reported Total Liabilities over the past 13 years, most recently at $23.8 million for Q3 2023.
- Quarterly results put Total Liabilities at $23.8 million for Q3 2023, up 12.91% from a year ago — trailing twelve months through Sep 2023 was $23.8 million (up 12.91% YoY), and the annual figure for FY2022 was $33.5 million, up 88.18%.
- Total Liabilities for Q3 2023 was $23.8 million at Endonovo Therapeutics, up from $23.2 million in the prior quarter.
- Over the last five years, Total Liabilities for ENDV hit a ceiling of $33.5 million in Q4 2022 and a floor of $14.2 million in Q1 2020.
- Median Total Liabilities over the past 5 years was $20.0 million (2019), compared with a mean of $20.3 million.
- Biggest five-year swings in Total Liabilities: fell 28.59% in 2020 and later soared 88.18% in 2022.
- Endonovo Therapeutics' Total Liabilities stood at $23.8 million in 2019, then fell by 28.59% to $17.0 million in 2020, then increased by 4.72% to $17.8 million in 2021, then skyrocketed by 88.18% to $33.5 million in 2022, then dropped by 28.95% to $23.8 million in 2023.
- The last three reported values for Total Liabilities were $23.8 million (Q3 2023), $23.2 million (Q2 2023), and $25.6 million (Q1 2023) per Business Quant data.